EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Temporal Galactose‐Manganese Feeding in Fed‐Batch and Perfusion Bioreactors Modulates UDP‐Galactose Pools for Enhanced mAb Glycosylation Homogeneity

Aron Gyorgypal iD, Erica Fratz-Berilla iD, Casey Kohnhorst, David N Powers, Shishir P S Chundawat iD

Biotechnology and Bioengineering · 2025

DOI: 10.1002/bit.28999 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2025. Verfasst von Aron Gyorgypal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biochemical Engineering, Rutgers The State University of New Jersey, Piscataway, New Jersey, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Bioreactors, Batch Cell Culture Techniques, Galactose. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported in part by award #PC5.2-112 granted to Rutgers University under a Project Award Agreement from the National Institute for Innovation i….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies (mAbs) represent a majority of biotherapeutics in the market today. These glycoproteins undergo posttranslational modifications, such as N‐linked glycosylation, that influence the structural & functional characteristics of the antibody. Glycosylation is a heterogenous posttranslational modification that may influence therapeutic glycoprotein stability and clinical efficacy, which is why it is often considered a critical quality attribute (CQA) of the mAb product. While much is known about the glycosylation pathways of Chinese Hamster Ovary (CHO) cells and how cell culture chemical modifiers may influence the N‐glycosylation profile of the final product, this knowledge is often based on the final cumulative glycan profile at the end of the batch process. Building a temporal understanding of N‐glycosylation and how mAb glycoform composition responds to real‐time changes in the biomanufacturing process will help build integrated process models that may allow for glycosylation control to produce a more homogenous product. Here, we look at the effect of specific nutrient feed media additives (e.g., galactose, manganese) and feeding times on the N‐glycosylation pathway to modulate N‐glycosylation of a Herceptin biosimilar mAb (i.e., Trastuzumab). We deploy the N‐GLYcanyzer process analytical technology (PAT) to monitor glycoforms in near real‐time for bench‐scale bioprocesses operated in both fed‐batch and perfusion modes to build an understanding of how temporal changes in mAb N‐glycosylation are dependent on specific media additives. We find that Trastuzumab terminal galactosylation is sensitive to media feeding times and intracellular nucleotide sugar pools. Temporal analysis reveals an increased desirable production of single and double galactose‐occupied glycoforms over time under glucose‐starved fed‐batch cultures. Comparable galactosylation profiles were also observed between fed‐batch (nutrient‐limited) and perfusion (non‐nutrient‐limited) bioprocess conditions. In summary, our results demonstrate the utility of real‐time monitoring of mAb glycoforms and feeding critical cell culture nutrients under fed‐batch and perfusion bioprocessing conditions to produce higher‐quality biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBioreactorsBatch Cell Culture TechniquesGalactoseCricetulusCHO CellsGlycosylationAnimalsCulture MediaCricetinae

Stichwörter der Autor:innen

N‐linked glycosylationbioprocessingmonoclonal antibodyperfusion

Substanzen

Antibodies, MonoclonalGalactoseCulture Media

Autor:innen und Institutionen

  • Department of Chemical and Biochemical Engineering, Rutgers The State University of New Jersey, Piscataway, New Jersey, USA.
  • Office of Pharmaceutical Quality Research, CDER, U.S. FDA, Silver Spring, Maryland, USA.
  • Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Aron Gyorgypal, Erica Fratz-Berilla, Shishir P S Chundawat

Förderung

  • This study was supported in part by award #PC5.2-112 granted to Rutgers University under a Project Award Agreement from the National Institute for Innovation i…

Zitieren

APA

Gyorgypal, A., Fratz-Berilla, E., Kohnhorst, C., Powers, D. N., & Chundawat, S. P. S. (2025). Temporal Galactose‐Manganese Feeding in Fed‐Batch and Perfusion Bioreactors Modulates UDP‐Galactose Pools for Enhanced mAb Glycosylation Homogeneity. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28999

Vancouver

Gyorgypal A, Fratz-Berilla E, Kohnhorst C, Powers DN, Chundawat SPS. Temporal Galactose‐Manganese Feeding in Fed‐Batch and Perfusion Bioreactors Modulates UDP‐Galactose Pools for Enhanced mAb Glycosylation Homogeneity. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.28999

BibTeX
@article{Gyorgypal2025,
  author = {Gyorgypal, Aron and Fratz-Berilla, Erica and Kohnhorst, Casey and Powers, David N and Chundawat, Shishir P S},
  title = {Temporal Galactose‐Manganese Feeding in Fed‐Batch and Perfusion Bioreactors Modulates UDP‐Galactose Pools for Enhanced mAb Glycosylation Homogeneity},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  doi = {10.1002/bit.28999}
}
Kostenlos starten →